poisar

Stocks · News reference

ADC Therapeutics Q2 2026 Earnings Call Transcript

Benzinga Insights

On Thursday, ADC Therapeutics (NYSE:ADCT) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ADCT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — ADC Therapeutics SA (ADCT)

    Filed: 2026-10-13 AccNo: 0000950103-26-015465 Size: 808 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

    ADCT